Abstract 3746: Association with the sonic hedgehog pathway between gastric cancer stem cells.

Author(s):  
Jae Sook Sung ◽  
Jong Won Lee ◽  
Ukhyun Jo ◽  
Yeul Hong Kim
2019 ◽  
Vol 70 (5) ◽  
pp. 570-578 ◽  
Author(s):  
Miaomiao Ge ◽  
Lu Zhang ◽  
Lina Cao ◽  
Chunfeng Xie ◽  
Xiaoting Li ◽  
...  

2018 ◽  
Vol 50 (6) ◽  
pp. 586-596 ◽  
Author(s):  
Libin Song ◽  
Xiangyuan Chen ◽  
Peng Wang ◽  
Song Gao ◽  
Chao Qu ◽  
...  

2015 ◽  
Vol 369 (1) ◽  
pp. 124-133 ◽  
Author(s):  
Min Xu ◽  
Aihua Gong ◽  
Hongqiong Yang ◽  
Suraj K. George ◽  
Zhijun Jiao ◽  
...  

2017 ◽  
Vol 493 (1) ◽  
pp. 521-527 ◽  
Author(s):  
Dengdian Wang ◽  
Xiaochuan Kong ◽  
Yuan Li ◽  
Weiwei Qian ◽  
Jiaxing Ma ◽  
...  

Author(s):  
Wanshuang Cao ◽  
Yuan Li ◽  
Hongliang Sun ◽  
Chenying Yang ◽  
Jianyun Zhu ◽  
...  

The presence of gastric cancer stem cells (GCSCs) marks the onset of gastric carcinoma. The sonic hedgehog (SHH) pathway plays a vital role in the maintenance of GCSC characteristics. Apatinib has been approved in China for advanced gastric cancer (GC) treatment. However, whether apatinib can target GCSCs and affect the SHH pathway remains unclear. The present study aimed to investigate the underlying mechanism of apatinib’s antitumor effects on GC. The expression levels of GCSC markers and number of CD133+ cells were significantly elevated in the sphere-forming cells. Apatinib effectively suppressed GCSC traits by inhibiting tumorsphere formation and cell proliferation, suppressing GCSC markers expression and CD133+ cell number, and inducing apoptosis. Apatinib downregulated the activation of the SHH pathway; while upregulation of the SHH pathway attenuated the inhibitory effects of apatinib on GCSCs. Moreover, apatinib treatment significantly delayed tumor growth and inhibited GCSC characteristics in the xenograft model. Our data suggested that apatinib exhibited inhibitory effects on GCSCs by suppressing SHH pathway both in vitro and in vivo, thus providing new insights into the therapeutic application of apatinib in GCSC suppression and advanced gastric cancer treatment.


Oncogenesis ◽  
2018 ◽  
Vol 7 (3) ◽  
Author(s):  
Weiwei Qian ◽  
Xiaochuan Kong ◽  
Tao Zhang ◽  
Dengdian Wang ◽  
Jin Song ◽  
...  

2020 ◽  
Vol 21 (2) ◽  
Author(s):  
Dengdian Wang ◽  
Dongdong Xie ◽  
Liangkuan Bi ◽  
Yi Wang ◽  
Ci Zou ◽  
...  

2020 ◽  
Author(s):  
Wanshuang Cao ◽  
Yuan Li ◽  
Hongliang Sun ◽  
Jianyun Zhu ◽  
Chunfeng Xie ◽  
...  

Abstract Background Gastric cancer stem cells (GCSCs) are considered as the basis of gastric carcinoma onset. Sonic Hedgehog (SHH) pathway plays a crucial role in maintaining GCSCs characteristics. Apatinib, a highly selective vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, has been approved in China for the treatment of advanced gastric cancer after the failure of second-line therapy. To data, the effects of apatinib on GCSCs and the underlying mechanisms have not been elucidated yet.Methods Tumorsphere formation assay was used to enrich GCSCs from BGC-823 and SGC-7901 cells and the number of CD133-positive cells was examined by flow cytometry. Western blotting, immunofluorescence and immunohistochemistry assays were used to determine protein expression. Cell proliferation and apoptosis of GCSCs after apatinib treatment were evaluated by CCK8, colony formation, flow cytometry and Hoechst 33258 assays. Transient transfection assay was used to upregulate Gli1 expression in GCSCs. Nude mouse xenograft was used to investigate the suppressive effects of apatinib in vivo. Results We revealed that the levels of GCSCs markers and the number of CD133-positive cells were significantly elevated in the sphere-forming cells. We further illustrated that apatinib efficiently abolished GCSCs traits, as manifested by inhibition of tumorsphere formation, decreased expression of GCSCs markers, reduced number of CD133-positive cells, drug resistance protein suppression as well as proliferation inhibition and apoptosis induction. Furthermore, we found that apatinib downregulated the activation of SHH pathway, while upregulation of SHH pathway attenuated the inhibitory effects of apatinib on GCSCs. Furthermore, apatinib treatment significantly delayed tumor growth and inhibited GCSCs characteristics in xenograft model. Conclusions Taken together, our data suggested that apatinib exhibited its inhibitory effects on GCSCs via suppression of SHH pathway. These findings could provide new insights into the therapeutic application of apatinib in GCSCs suppression and advanced gastric cancer treatment.


Sign in / Sign up

Export Citation Format

Share Document